ReviewFrontiers in immunology2026
Progress and prospects for herpesvirus vaccination using gB antigens.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of vaccines against varicella zoster virus (VZV) demonstrates the feasibility of high-level efficacy against clinical consequences of herpesvirus infection, but there is a need for new vaccines against others - in particular Epstein-Barr Virus (EBV), human cytomegalovirus (HCMV) and herpes simplex virus 1 and 2 (HSV). Herpesviruses use surface glycoproteins to trigger membrane fusion during cell invasion. Glycoprotein B (gB) is conserved across the family and acts as the fusogen. Vaccines based upon viral fusion proteins protect against many other viruses, and a gB-targeting HCMV vaccine achieved partial efficacy in clinical trials. This experience encourages development of improved gB-based antigens and formulations. There has recently been progress in stabilisation of the pre-fusion conformation of gB, which may be the more relevant structure with respect to immunological protection. Nonetheless gB-targeting vaccines have received less attention recently than vaccines against receptor-binding glycoproteins such as EBV gH/gL and gp350, and HCMV pentamer. We therefore seek to review current knowledge regarding gB as a vaccine antigen: understanding of herpesvirus gB structure and function, within the context of the wider process of herpesvirus entry into host cells; insights relevant to vaccine development from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.